United Therapeutics Corp. (NASDAQ:UTHR) said Thursday it has acquired privately held Thymmune Therapeutics.
Thymmune is a preclinical biotechnology company developing regenerative thymic cell therapies designed to restore immune function and improve transplant outcomes.
Acquisition Includes Milestone-Based Payments
Under the agreement, United Therapeutics will pay $140 million in cash, subject to certain post-closing adjustments.
United Therapeutics reported cash and cash equivalents of $1.28 billion as of March 31, 2026.
Former Thymmune shareholders are also eligible for up to $160 million in additional earn-out payments tied to clinical and regulatory milestones through the end of 2031.
Deal Brings Preclinical Thymic Cell Therapy Platform
Thymmune is a preclinical-stage biotechnology company developing regenerative thymic cell therapies designed to address post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.
Its technology uses a proprietary process to convert human-induced pluripotent stem cells (iPSCs) into thymic cells. Once implanted, these cells mature into multiple cell types capable of restoring healthy T-cell function, a key component of the immune system responsible for fighting infections and disease.
The thymus plays a central role in developing and training T-cells, making it essential for maintaining a functional immune system.
Lead Candidate Targets Rare Immune Disorder
Thymmune’s lead candidate, THY-100, is being developed for congenital athymia, an ultra-rare condition in which infants are born without a functioning thymus.
According to the company, preclinical animal studies have shown that THY-100 can generate a neo-thymus inside the body that supports T-cell development.
If clinical proof of concept is established, the therapy could enable broader applications in thymic regenerative medicine, including transplant tolerance, immune-mediated diseases, and improving immune function in older adults with declining T-cell activity.
UTHR Stock Price Activity: United Therapeutics shares were up 1.24% at $553.93 during premarket trading on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
